\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes HealthThe European Partnership on Rare Diseases (ERDERA) has preannounced its first Joint Transnational Call for Proposals on Rare Disease Therapies. The content of the preannouncement may be subject to change.
The call will formally open on 10 December and will have a two-stage submission process with deadline for pre-proposals in February 2025 and full proposal deadline in July 2025.
Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on who can apply & how will become available on the FWO website after official opening of the call.
The primary objective of the call is to support interdisciplinary, transnational collaborations that leverage complementary expertise to develop new therapies for rare diseases. Research projects should focus on pre-clinical studies involving small molecules or biologicals. This could include the development of novel therapies, biomarkers for therapy efficiency, or replication of pre-clinical studies to validate findings.
More information is available on the ERDERA website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
